- Research article
- Open Access
Gastrointestinal adverse effects of varenicline at maintenance dose: a meta-analysis
BMC Clinical Pharmacologyvolume 11, Article number: 15 (2011)
Tobacco smoking remains the leading modifiable health hazard and varenicline is amongst the most popular pharmacological options for smoking cessation. The purpose of this study is to critically evaluate the extent of gastrointestinal adverse effects of varenicline when used at maintenance dose (1 mg twice a day) for smoking cessation.
We conducted a meta-analysis of randomised controlled trials published in PUBMED and EMBASE according to the PRISMA guidelines. Selected studies satisfied the following criteria: (i) duration of at least 6 weeks, (ii) titrated dose of varenicline for 7 days then a maintenance dose of 1 mg twice-per-day, (iii) randomized placebo-controlled design, (iv) extractable data on adverse event - nausea, constipation or flatulence. Data was synthesized into pooled odd ratios (OR) basing on random effects model. Quality of studies was also rated as per Cochrane risk-of-bias assessment. Number need to harm (NNH) was calculated for each adverse effect.
98 potentially relevant studies were identified, 12 of which met the final inclusion criteria (n = 5114). All 12 studies reported adverse events on nausea, which led to an OR of 4.45 (95% CI = 3.79-5.23, p < 0.001; I2 = 0.06%, CI = 0%-58.34%) and a NNH of 5. Eight studies (n = 3539) contain data on constipation pooled into an OR of 2.45 (95% CI = 1.61-3.72, p < 0.001; I2 = 34.09%, CI = 0%-70.81%) with a NNH of 24. Finally, five studies (n = 2516) reported adverse events of flatulence, which pooled an OR of 1.74 (95% CI = 1.23-2.48, p = 0.002; I2 = 0%, CI = 0%- 79.2%) with a NNH of 35.
Use of varenicline at maintenance dose of 1 mg twice a day for longer than 6 weeks is associated with adverse gastrointestinal effects. In realistic terms, for every 5 treated subjects, there will be an event of nausea, and for every 24 and 35 treated subjects, we will expect an event of constipation and flatulence respectively. Family physicians should counsel patients of such risks accordingly during their maintenance therapy with varenicline.
Tobacco smoking remains the most modifiable risk factor for premature death and all-cause mortality , with a global estimate of 4.83 million attributable deaths in year 2000 . As a result, many pharmacological agents have been developed to help patients stop tobacco smoking, some of which can be administered either nasally, orally (chewable gum or tablets) or topically (e.g., nicotine replacement patch). Amongst these agents, varenicline (branded as Champix© in UK and Canada, Chantix© in USA) has been shown to be the one of the most effective oral pharmacological agents for continued abstinence. Varenicline acts as a partial α4β2 nicotinic acetylcholine receptor agonist in the brain to potentially decrease the degree of cravings and withdrawal symptoms during the period of smoking cessation, with effects superior to both placebos and other pharmacological agents . Animal studies have found that tobacco addiction is mediated via nicotinic acetylcholine receptors (nAChRs) in the meso-limbic area of the brain that contain α4 and β2 subunits. While α4 subunits are needed for sensitization and reinforcement to nicotinic effects and their tolerance, involvement of β2 subunits are indispensable for development of dependence . In vivo studies have shown that in the presence of nicotine, varenicline acts as a partial agonist which stimulates the release of dopamine (to ameliorate the symptoms of craving and withdrawal) and simultaneously block the nicotine receptors (to reduce the likelihood of dependence)[5, 6]. When compared to other mainstream pharmacotherapies (e.g., nicotine replacement therapy and bupropion), varenicline remains as the most effective choice for smoking cessation  and is validated by high-quality meta-analysis . Nevertheless, varenicline has been associated with adverse events like headache, fatigue, sleep disorder, nausea and constipation [9, 10]. Whilst risks of neuropsychiatric adverse events due to varenicline have already been reported in a polled analysis , the likelihood of major gastrointestinal adverse effects (such as nausea, constipation and flatulence) during maintenance phase lacks precise documentation. We hereby performed a meta-analysis of randomized double-blinded placebo-controlled trials to critically examine the relative risks of nausea, constipation and flatulence due to maintenance dose of varenicline (1 mg twice a day for at least 6 weeks) in the context of smoking cessation.
Our primary interest was the reported gastrointestinal adverse-effects in using varenicline at the indicated maintenance dose (1 mg) for duration longer than six weeks. To minimise heterogeneity, we limited our scope to double-blind randomised placebo-controlled trials with comparable sample sizes and a satisfactory score from the Cochrane risk of bias assessment tool described by Higgins . Eligible studies must use a one-week titrated dose (0.5 mg) of varenicline prior to maintenance dose (1 mg twice a day), and contain at least one extractable adverse gastrointestinal event of nausea, constipation or flatulence.
A literature search of published medical reports was performed in all languages from PUBMED (from 1947 to December 2010), EMBASE (from 1947 to December 2010) and All EBM Reviews using the OVID Portal of Queen's University, Kingston, Ontario. Abstracts were initially obtained using keywords of "smoking cessation" AND "varenicline. They were further narrowed down by imposing keywords of "human" AND "controlled trial". Manual searches of references and review articles supplemented the computerized search.
Study selection, data extraction and quality assessment
Two reviewers (LL and FP) worked independently and went over the initial search for abstracts that satisfied the keywords as mentioned in the search strategy section. They then adopted a simple form to select trials that satisfied the eligibility criteria stated above. Evaluation of selected studies were performed independently by each reviewer according to the Cochrane risks of bias tool  in regards to the quality of study, randomization protocol, adequacy of concealment and blinding and, rigor of follow-up for dropouts. Information was extracted and tabulated in spreadsheet regarding the demography of the study population, duration of study, the types of adverse events, the number of affected subjects taking varenicline and placebo respectively and finally a numeric score for the Cochrane risk of bias. Spreadsheets were compared and any disagreement was discussed and resolved to reach mutual consensus.
All data were synthesized in a meta-analysis and odds ratios (OR) were calculated with appropriate confidence intervals (CI) basing on the number of subjects reporting the relevant adverse effects in the study. Where necessary, the value of 1 was added to any arm with zero outcome event according to the Sheele +1 rule . The random effects analysis model as described by DerSimonian and Laird  was adopted instead of the fixed effects model to account for extra variance due to heterogeneous samples drawn from a wide population . Forest plots  were generated basing on OR for each gastrointestinal symptom of nausea, constipation and flatulence. Basing on the values of OR and the baseline risks of adverse effects, the number needed to harm (NNH) was also calculated which gives a realistic idea of the likelihood of the adverse effects. Funnel plots  were displayed as a reference for possible publication bias. To assess heterogeneity across included studies, we adopted the Cochran Q-statistic  and the I2 index [19, 20] with 95% confidence intervals. We assumed a p-value of less than 0.10 for the Cochran Q-statistic and an I2 index of greater than 50% as a threshold of heterogeneity. Statistical advice was provided by data analyst at our Centre of Studies in Primary Care.
1431 abstracts were identified using keywords of "smoking cessation" AND "varenicline", which were reduced to 108 abstracts when imposing extra keywords of "human" AND "controlled trial" with supplementation from reference lists of included abstracts. 10 duplicates were removed and 82 abstracts were further excluded on grounds of having no placebo control group, combined mixed treatments, no relevant gastrointestinal adverse events data, or duplication trial publication or report. 16 relevant full text paper publications were then retrieved for potential inclusion. After imposing the eligibility criteria as described, only 12 studies were deemed eligible upon which mutual consensus was reached between the reviewers after discussion and comparison of the data spreadsheets. Using the 2009 PRISMA checklist  (Additional File 1), all 27 items were present and identified scored. A flow diagram of the literature search and selection process according to the PRISMA format  was given in Figure 1, and the included studies were tabulated in Table 1. From the 12 studies, 2,622 patients were randomly assigned to receive varenicline (oral dose of 1 mg twice per day), and 2,492 patients were randomly assigned to receive placebo. Total sample size per study ranged from 248 to 714 and three studies had a total size of greater than 500. Except for the study by Tashkin et al.  which specifically targeted patients with COPD, all other studies recruited subjects from the general population. One trial used varenicline for 6 weeks  while another for 52 weeks , the rest used 12 weeks. All but one study  employed the standard low-dose titration regime before using the 1 mg twice per day dosage. There was no exclusion as for the type of tobacco used by smokers in all trials except for the study by Fagerstrom et al.  which recruited subjects using smokeless tobacco.
Assessment of study quality
All 12 studies achieved a score of at least 4 out of 6, using the Cochrane risk of bias assessment  (See table 1) and was considered satisfactory with mutual agreement between the two reviewers. After consultation with our statistician, the random effects model was adopted for subsequent analysis.
All 12 studies [9, 22–32] reported adverse effects of nausea with a total sample size of 5114. Out of the total 2622 subjects randomized to varenicline, 826 reported nausea; of the 2492 subjects taking placebo, 232 had nausea. The pooled OR was 4.45 (95% confidence levels [CI] of 3.79-5.23, p < 0.001) with a non-significant Cochrane Q-statistic of 11.01 (p = 0.443) and an I2 index of 0.06% (95% confidence levels of 0% - 58.34%). With a baseline risk of nausea at 9.3%, the number need to harm (NNH) is 5. The Forest plot was shown in Figure 2 and funnel plot in Additional File 2.
8 studies [23–30] reported adverse effects of constipation with a total sample size of 3539. 146 of 1839 subjects in the varenicline group and 53 of 1700 in the control group reported adverse effects of constipation. The pooled OR was 2.45 (95% confidence levels [CI] of 1.61-3.72, p < 0.001) with a non-significant Cochrane Q-statistic of 10.62 (p = 0.156) and an I2 index of 34.09% (95% confidence levels of 0% - 70.81%). The baseline risk of constipation is 3.1%, yielding a NNH of 24. The Forest plot was shown in Figure 3 and the funnel plot in Additional File 2.
5 studies [22, 24, 25, 27, 30] were included reporting adverse effects of flatulence with a total sample size of 2516 subjects. 102 of 1325 subjects in the varenicline group and 50 of 1191 in the control group reported adverse effects of flatulence. The pooled OR was 1.74 (95% confidence levels [CI] of 1.23-2.48, p = 0.002) with a non-significant Cochrane Q-statistic of 1.82 (p = 0.768) and an I2 index of 0% (95% confidence levels of 0% - 79.2%). With a baseline risk of flatulence at 4.2%, the NNH is 35. The Forest plot was shown in Figure 4 and the funnel plot in Additional File 2.
Our meta-analysis data confirms that using varenicline at maintenance dose of 1 mg twice per day for a period of more than 6 weeks is significantly associated with adverse effects of nausea and, to a lesser extent, constipation and flatulence. Using pooled odds ratios (OR) and subsequently translating them to number need to harm (NNH), we showed that for nausea, constipation and flatulence, the NNH is 5, 24 and 35 respectively. Such numbers provide clinicians with a realistic picture of the likelihood for gastrointestinal adverse effects when prescribing varenicline as a drug of choice for smoking cessation. As the commonest gastrointestinal adverse effect, nausea accounts for failure of varenicline treatment amongst 1.8% to 7.6% of our study population [24, 26, 27, 30, 31]. The effects of nausea usually peak around 4 weeks of treatment and becoming less thereafter . No similar discontinuation rates due to effects of constipation or flatulence have been reported.
Limitation of studies
Our study has two limitations. Gastrointestinal adverse effects like nausea and flatulence are primarily subjective feelings which are difficult to quantify, despite crude stratification into mild, moderate or severe in several studies. Definition for constipation is also not standardised as per Rome criteria  amongst the included studies in terms of bowel frequency or patient's difficulty in defecation. They may constitute data heterogeneity across studies in our meta-analysis.
The second limitation is the potential of publication bias. Our search strategy only isolated full-length published trials with sufficient population sizes to maintain statistical significance. In addition, we excluded studies with populations less than 40. However adoption of the random effects model in meta-analysis will help compensate irregularities due to small and potentially negative studies that we have excluded. Our funnel plots do not show obvious asymmetry (Additional File 2), suggesting the low likelihood of publication bias in our analysis. Thus said, the visual asymmetry of funnel plots should not be used to confirm the extent of publication bias , especially when the number of studies is small . The I2 index suggests very low heterogeneity across studies for both nausea and flatulence (both at 0%) and slightly higher but still acceptable heterogeneity for constipation (34%). Like the Cochran Q-statistic, the I2 index is known to have limitations with its power affected by the actual number of included studies .
Varenicline is one of the most preferred pharmacological options for smoking cessation and gastrointestinal adverse effects have been mentioned but not documented precisely. Our comprehensive meta-analysis on randomised double-blind placebo-controlled trials concluded that in realistic terms, use of varenicline at the indicated maintenance dose (1 mg twice per day) for longer than 6 weeks will lead to one adverse event of nausea for every 5 treated subjects, one event of constipation for every treated 24 subjects and one event of flatulence for every 35 treated subjects. These data will better enable clinicians in counseling patients when using varenicline for smoking cessation both in facilitating and reinforcing optimal smoking cessation rate.
Conflict of interests
The authors declare that they have no competing interests.
Peto R, Lopez AD, Boreham J, Thun M, Heath C, Doll R: Mortality from smoking worldwide. Br Med Bull. 1996, 52 (1): 12-21.
Ezzati M, Lopez AD: Regional, disease specific patterns of smoking-attributable mortality in 2000. Tob Control. 2004, 13 (4): 388-395. 10.1136/tc.2003.005215.
Keating GM, Lyseng-Williamson KA: Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation. Pharmacoeconomics. 2010, 28 (3): 231-254. 10.2165/11204380-000000000-00000.
Foulds J: The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract. 2006, 60 (5): 571-576. 10.1111/j.1368-5031.2006.00955.x.
Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC: Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology. 2007, 52 (3): 985-994. 10.1016/j.neuropharm.2006.10.016.
Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB: Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005, 48 (10): 3474-3477. 10.1021/jm050069n.
Garrison GD, Dugan SE: Varenicline: a first-line treatment option for smoking cessation. Clin Ther. 2009, 31 (3): 463-491. 10.1016/j.clinthera.2009.03.021.
Mills EJ, Wu P, Spurden D, Ebbert JO, Wilson K: Efficacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysis. Harm Reduct J. 2009, 6: 25-10.1186/1477-7517-6-25.
Fagerstrom K, Gilljam H, Metcalfe M, Tonstad S, Messig M: Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial. BMJ. 2010, 341: c6549-10.1136/bmj.c6549.
Fagerstrom K, Nakamura M, Cho HJ, Tsai ST, Wang C, Davies S, Ma W, Lee TC, Russ C: Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebo-controlled trials conducted in six Asian countries. Curr Med Res Opin. 2010, 26 (9): 2165-2173. 10.1185/03007995.2010.505130.
Tonstad S, Davies S, Flammer M, Russ C, Hughes J: Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf. 2010, 33 (4): 289-301. 10.2165/11319180-000000000-00000.
Higgins JAD: Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions. 2008, John Wiley and Sons, 187-241. 1
Sheehe PR: Combination of log relative risk in retrospective studies of disease. Am J Public Health Nations Health. 1966, 56 (10): 1745-1750. 10.2105/AJPH.56.10.1745.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials. 1986, 7 (3): 177-188. 10.1016/0197-2456(86)90046-2.
Fleiss JL: The statistical basis of meta-analysis. Stat Methods Med Res. 1993, 2 (2): 121-145. 10.1177/096228029300200202.
Lewis S, Clarke M: Forest plots: trying to see the wood and the trees. BMJ. 2001, 322 (7300): 1479-1480. 10.1136/bmj.322.7300.1479.
Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315 (7109): 629-634.
Cochran WG: The combination of estimates from different experiments. Biometrics Vol. 1954, 10: 101-129. 10.2307/3001666.
Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med. 2002, 21 (11): 1539-1558. 10.1002/sim.1186.
Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ. 2003, 327 (7414): 557-560. 10.1136/bmj.327.7414.557.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009, 339: b2700-10.1136/bmj.b2700.
Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC: Effects of Varenicline on Smoking Cessation in Mild-to-Moderate COPD: A Randomized Controlled Trial. Chest. 2010
Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, Reeves KR: Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006, 166 (15): 1561-1568. 10.1001/archinte.166.15.1561.
Williams KE, Reeves KR, Billing CB, Pennington AM, Gong J: A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin. 2007, 23 (4): 793-801. 10.1185/030079907X182185.
Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R, Reeves K: Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006, 166 (15): 1571-1577. 10.1001/archinte.166.15.1571.
Tsai ST, Cho HJ, Cheng HS, Kim CH, Hsueh KC, Billing CB, Williams KE: A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther. 2007, 29 (6): 1027-1039. 10.1016/j.clinthera.2007.06.011.
Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR: Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006, 296 (1): 56-63. 10.1001/jama.296.1.56.
Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR: Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther. 2007, 29 (6): 1040-1056. 10.1016/j.clinthera.2007.06.012.
Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S: Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010, 121 (2): 221-229. 10.1161/CIRCULATIONAHA.109.869008.
Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR: Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006, 296 (1): 47-55. 10.1001/jama.296.1.47.
Wang C, Xiao D, Chan KP, Pothirat C, Garza D, Davies S: Varenicline for smoking cessation: a placebo-controlled, randomized study. Respirology. 2009, 14 (3): 384-392. 10.1111/j.1440-1843.2008.01476.x.
Niaura R, Hays JT, Jorenby DE, Leone FT, Pappas JE, Reeves KR, Williams KE, Billing CB: The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr Med Res Opin. 2008, 24 (7): 1931-1941. 10.1185/03007990802177523.
Drossman DA: Rome III: the new criteria. Chin J Dig Dis. 2006, 7 (4): 181-185. 10.1111/j.1443-9573.2006.00265.x.
Terrin N, Schmid CH, Lau J: In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. J Clin Epidemiol. 2005, 58 (9): 894-901. 10.1016/j.jclinepi.2005.01.006.
Song F, Khan KS, Dinnes J, Sutton AJ: Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol. 2002, 31 (1): 88-95. 10.1093/ije/31.1.88.
Ioannidis JP, Patsopoulos NA, Evangelou E: Uncertainty in heterogeneity estimates in meta-analyses. BMJ. 2007, 335 (7626): 914-916. 10.1136/bmj.39343.408449.80.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6904/11/15/prepub
LL and FP designed the review and performed the literature search. LL performed the analysis and generation of the graphic plots. LL and FP analysed and interpreted the data and both contributed to the drafting of the manuscript. WR provided comments and advice on the overall study. ALL authors have read and approved the submitted version for publication.